# Study to Assess the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ABT-267 in HCV Infected Subjects

> **NCT01563536** · PHASE2 · COMPLETED · sponsor: **AbbVie (prior sponsor, Abbott)** · enrollment: 12 (actual)

## Conditions studied

- Chronic Hepatitis C Infection

## Interventions

- **DRUG:** ABT-267
- **DRUG:** ABT-450
- **DRUG:** ABT-333
- **DRUG:** Ritonavir
- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT01563536
- **Lead sponsor:** AbbVie (prior sponsor, Abbott)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-02
- **Primary completion:** 2012-04
- **Final completion:** 2013-06
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2018-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01563536

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01563536, "Study to Assess the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ABT-267 in HCV Infected Subjects". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01563536. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*